OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-12.26%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$277M
AUM Growth
+$277M
(-16%)
Cap. Flow
+$6.82M
Cap. Flow
% of AUM
2.47%
Top 10 Holdings %
Top 10 Hldgs %
42.56%
Holding
60
New
17
Increased
8
Reduced
14
Closed
11
Top Buys
| 1 |
Stereotaxis
STXS
|
$14.3M |
| 2 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$10.8M |
| 3 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$8.04M |
| 4 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$4.79M |
| 5 |
Quanterix
QTRX
|
$4.06M |
Top Sells
| 1 |
Lexicon Pharmaceuticals
LXRX
|
$9.31M |
| 2 |
CMRX
Chimerix, Inc.
CMRX
|
$6.35M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
$5.75M |
| 4 |
Arvinas
ARVN
|
$4.84M |
| 5 |
Viking Therapeutics
VKTX
|
$3.32M |
Sector Composition
| 1 | Healthcare | 97.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMRX
51
DELISTED
Chimerix, Inc.
CMRX
| – | – |
-1,470,000
| Closed | -$6.35M |
|
|
ENTO
52
Entero Therapeutics
ENTO
$4.4M
| – | – |
-1
| Closed | -$247K |
|
|
53
Viking Therapeutics
VKTX
$3.02B
| – | – |
-400,000
| Closed | -$3.32M |
|
54
Protalix BioTherapeutics
PLX
$128M
| – | – |
-100,000
| Closed | -$469K |
|
|
55
Lexicon Pharmaceuticals
LXRX
$392M
| – | – |
-1,480,000
| Closed | -$9.31M |
|
|
56
Ironwood Pharmaceuticals
IRWD
$201M
| – | – |
-525,400
| Closed | -$5.75M |
|
57
Fennec Pharmaceuticals
FENC
$247M
| – | – |
-295,000
| Closed | -$1.18M |
|
|
58
Arvinas
ARVN
$580M
| – | – |
-220,000
| Closed | -$4.84M |
|
59
Aquestive Therapeutics
AQST
$478M
| – | – |
-590,000
| Closed | -$2.48M |
|